Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, outlines the indications for brentuximab vedotin in Hodgkin lymphoma (HL) and comments on the management of brentuximab vedotin-induced peripheral sensory neuropathy. Brentuximab vedotin is currently used in a wide range of settings in HL, including frontline and consolidation therapy. Peripheral sensory neuropathy is a common side effect induced by brentuximab vedotin. Guidelines for the management of this adverse event recommend decreasing the drug dose or increasing the time interval between each dose. Patients who still experience neurotoxicity after this should stop using the drug definitively. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
